Sandoz has announced that it has received a Complete Response Letter from the FDA for GP2013, its proposed rituximab biosimilar referencing Rituxan.
Sandoz has announced that it has received a Complete Response Letter from the FDA for GP2013, its proposed rituximab biosimilar referencing Rituxan.
The company said in a statement that “Sandoz stands behind the robust body of evidence included in the regulatory submission and is currently evaluating the content of the letter. While disappointed, Sandoz remains committed to further discussions with FDA in order to bring this important medicine to US patients as soon as possible.”
Sandoz filed its Biologics License Application for GP2013 in the US in September 2017, following European approval of the drug, for marketing under the brand name Rixathon, in June 2017. The company had hoped to gain approval in all of the approved indications of the reference product: follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis, and microscopic polyangiitis.
In June 2017, Sandoz released primary results from the ASSIST-FL phase 3 trial of GP2013 in patients with advanced follicular lymphoma. The primary endpoint was comparability in overall response, with equivalence shown if the entire 95% confidence interval (CI) was within an equivalence margin of -12% to 12%. The primary endpoint was analyzed in patients who had received at least 1 (partial or complete) dose of the investigational treatment and who did not have any major protocol deviations. The primary endpoint was met: 271 of 311 patients (87%) receiving GP2013 and 274 of 313 patients (88%) receiving reference rituximab achieved an overall response. The 95% CI was within the predefined margin (range: -5.94 to 5.14).
Soon after, at the American College of Rheumatology's 2017 meeting in San Diego, California, researchers presented data that compared the safety and immunogenicity of switching from reference rituximab to GP2013 to continued treatment with reference rituximab in patients with active RA who had previously received reference rituximab prior to randomization into 2 treatment arms: 1 arm switched treatment to GP2013, and the control arm continued to receive reference rituximab.
The incidence of hypersensitivity was 9.4% in the switch group and 11.1% in the control group. Infusion-related reactions occurred in 11.3% and 18.5% of patients in each group, respectively, and the researchers concluded that the safety profile of patients who switched from the reference to the biosimilar was comparable with that of the patients who remained on the reference therapy.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.